agilon health, inc. revised earnings guidance for the year ending December 31, 2024. For the year, the company expects revised total revenues to be in the range of $6,125 million to $6,175 million compared to previously expected total revenues to be in the range of $6,350 million to $6,465 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.41 USD | -3.05% | +4.24% | -56.89% |
09/05 | Deutsche Bank Adjusts agilon health Price Target to $5 From $8, Maintains Hold Rating | MT |
07/05 | Transcript : Agilon health, inc., Q1 2024 Earnings Call, May 07, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-56.89% | 2.22B | |
-20.57% | 2.95B | |
-16.01% | 2.84B | |
-37.78% | 268M | |
+0.96% | 235M | |
-38.78% | 196M | |
-36.31% | 110M |
- Stock Market
- Equities
- AGL Stock
- News agilon health, inc.
- Agilon health, inc. Revises Earnings Guidance for the Year Ending December 31, 2024